Laurion Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurion Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,200	Closed	-$997K	–	506
2025 Q4	$997K	Buy	+2,200	New	+$948K	0.04%	131
2024 Q3	–	Sell	-1,248	Closed	-$585K	–	604
2024 Q2	$585K	Sell	1,248 -65,645	-98%	-$28.5M	0.01%	344
2024 Q1	$28M	Buy	+66,893	New	+$28.3M	0.24%	91
2022 Q4	–	Sell	-705	Closed	-$204K	–	557
2022 Q3	$204K	Buy	+705	New	+$203K	﹤0.01%	435
2022 Q2	–	Sell	-11,949	Closed	-$3.12M	–	715
2022 Q1	$3.12M	Buy	+11,949	New	+$2.84M	0.04%	182
2020 Q4	–	Sell	-73,975	Closed	-$20.1M	–	996
2020 Q3	$20.1M	Buy	+73,975	New	+$20.4M	0.24%	102
2019 Q4	–	Sell	-2,675	Closed	-$453K	–	1264
2019 Q3	$453K	Buy	+2,675	New	+$473K	﹤0.01%	785
2017 Q4	–	Sell	-5,700	Closed	-$867K	–	1881
2017 Q3	$867K	Sell	5,700 -16,882	-75%	-$2.54M	﹤0.01%	1022
2017 Q2	$2.91M	Sell	22,582 -235,800	-91%	-$28.4M	0.02%	688
2017 Q1	$28.3M	Buy	+258,382	New	+$22.7M	0.21%	115
2015 Q3	–	Sell	-2,417	Closed	-$298K	–	918
2015 Q2	$298K	Buy	+2,417	New	+$305K	﹤0.01%	528

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Laurion Capital Management's VRTX Position: Q1 2026 in Review

Laurion Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 2,200 shares — an estimated $997K sold.

Laurion Capital Management first reported a position in VRTX in Q2 2015 and held it in 11 quarters. The position peaked at $28.3M in Q1 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Laurion Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Laurion Capital Management sold 2,200 Vertex Pharmaceuticals shares in Q1 2026, an estimated $997K.
Laurion Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 11 quarters.
Laurion Capital Management's Vertex Pharmaceuticals position peaked at $28.3M in Q1 2017.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.